Acute leukaemia in chronic hepatitis B patients with lamivudine therapy.
PMID: 15605678
2004
International journal of clinical practice
Abstract: The first case developed acute myeloid leukaemia, 1 year after stopping lamivudine therapy, when A529T mutant HBV-DNA was still detectable.
Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
Abstract: Of them, 3 developed an alanine 529-to-threonine (A529T) mutant, 6 developed a leucine 528-to-methionine/methionine 552-to-isoleucine (L528M/M552I) mutant, and 1 developed these two mutants sequentially.
Abstract: The nucleotide substitution in the A529T mutant concomitantly generated a stop codon at the surface gene, leading to impaired secretion of HBsAg.
HBV mutation literature information.
PMID: 
2004
International journal of clinical practice
Browser Board
Co-occurred Entities
Filtrator